Qiagen NV at Robert W Baird Global Healthcare Conference Transcript
All right, great. I'm Catherine Schulte. I cover life sciences and diagnostics here at Baird. Very excited to have QIAGEN here joining us today. From the company, we have the CEO, Thierry Bernard. So thanks so much for joining us.
Thank you, and thanks for your attention and interest in QIAGEN. Thanks.
Questions & Answers
And we're going to dive right into Q&A. So if anyone from the audience has any questions, you can send it to [email protected], and I will pass it along.
So maybe to kick things off, just talk about your outlook for '23. I think the back half of the year, guidance implies 6% CER growth, which is markedly better than what we're seeing peers with instrumentation headwinds,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
